вторник, 26 июля 2016 г.

Gilead Lowers 2016 Net Product Sales Forecast, Shares Fall

Gilead Lowers 2016 Net Product Sales Forecast, Shares Fall


Gilead Sciences Inc. cut its product sales forecast for 2016 and reported lower-than-expected sales in the second quarter for its hepatitis C drugs, sending the shares lower in late trading. Net product sales will be $29.5 billion to $30.5 billion for the year, down from a previous forecast of $30 billion to $31 billion, Foster City, California-based Gilead said Monday in a statement.



from Biotech News